by MM360 Staff | Jul 30, 2025 | Uncategorized
Source: CureToday articles Panelists discuss how patients newly diagnosed with multiple myeloma often face emotional and informational overload, but collaborative, personalized care—including early access to cutting-edge four-drug regimens, clear communication, and...
by MM360 Staff | Jul 28, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Jul 28, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Jul 25, 2025 | Publications
Rofo. 2025 Jul 23. doi: 10.1055/a-2625-5643. Online ahead of print. ABSTRACT Multiple myeloma (MM) is the second most common hemato-oncological malignancy, characterized by the clonal proliferation of malignant plasma cells and bone marrow infiltration. The degree of...
by MM360 Staff | Jul 24, 2025 | Myeloma News
Source: Pharmacy Times articles Sundar Jagannath, MD, discusses how prophylactic tocilizumab reduced cytokine release syndrome incidence and severity with talquetamab in relapsed or refractory (R/R) multiple myeloma. Read More